Topical microbicides: Current status and research considerations for adolescent girls

Sexually Transmitted Diseases

Volumn 25, Issue 7, 1998, Pages 368-377

  Rosenthal, Susan L ^a,b   Cohen, Sheila S ^a,b   Stanberry, Lawrence R ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; BENZALKONIUM CHLORIDE; CARBOPOL 974P; CARRAGEENAN; CHLORHEXIDINE; CHOLIC ACID; CYANOVIRIN N; D 2A21; GEDA PLUS; IMIQUIMOD; MENFEGOL; NONOXINOL 9; OCTOXINOL 9; PRO 2000; PROTECTAID; REPROTECT; SPERMICIDAL AGENT; UNCLASSIFIED DRUG;

ADOLESCENCE; ADOLESCENT; ARTICLE; CHLAMYDIASIS; CONDYLOMA; FEMALE; FEMALE GENITAL TRACT INFECTION; GENITAL HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTRAVAGINAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION; SEXUAL MATURATION; SEXUALLY TRANSMITTED DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADOLESCENT PSYCHOLOGY; ANIMALS; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; MALE; SEXUALLY TRANSMITTED DISEASES;

EID: 0031848878     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199808000-00009     Document Type: Article

References (108)

1. Institute of Medicine. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. In: Eng TR, Butler WT, eds. Washington, DC: National Academy Press, 1997.
2. National Center for Health Statistics. Fertility, family planning, and women's health: New data from the 1995 National survey of Family Growth. Vital and Health Statistics, Series 23, No 19. Hyattsville, MD: National U.S. Department of Health and Human Services; DHHS Publication no. (PHS) 97.
3. Stein ZA. HIV prevention: The need for methods women can use. Am J Pub Health 1990; 80:460-462.
4. Farr G, Castro LAA, Disantostefano R, Claassen E, Olguin F. Use of spermicide and impact of prophylactic condom use among sex workers in Santa Fe de Bogota, Columbia. Sex Transm Dis 1996; 23:206-212.
5. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996; 10(suppl 3):S43-S51.
6. Future Barrier Methods and Microbicides, The Contraception Report. 1997; 8:4-14.
7. Rosenberg MJ, Holmes KK, and the World Health Organization working group on virucides. Virucides in prevention of HIV infection: Research priorities. Sex Transm Dis 1992; 20(1):41-44.
8. The International working group on vaginal microbicides. Recommendations for the development of vaginal microbicides. AIDS 1996; 10:1-6.
9. Elias CJ, Heise LL. Challenges for the development of female-controlled vaginal microbicides. AIDS 1994; 8:1-9.
10. Jennings R, Clegg A. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. J Antimicrob Chemother 1993; 32:71-82.
11. Asculai SS, Weis MT, Rancourt, MW, Kuphferberg AB. Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Ag Chemother 1978; 13:686-690.
12. Thompson KA, Malamud D, Storey BT. Assessment of the antimicrobial agent C31 as a spermicide: comparison with nonoxynol-9. Contraception 1996; 53:313-318.
13. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 use and genital irritation. Int J STD AIDS 1993; 4:165-170.
14. Cook RL, Rosenberg, MJ. Do spermicides containing nonoxynol-9 prevent sexually transmitted infections? A meta analysis. Sex Transm Dis 1998, 25:144-150.
15. Roddy RE, Shulz KF, Cates W. Microbicides, meta-analysis, and the N-9 question. Where's the research? Sex Trans Dis 1998; 25:151-153.
16. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada. September/October, 1997, Abstract H-53.
17. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87:427-436.
18. Su H, Raymond L, Rockey DD, Fischer E, Hackstadt T, Caldwell HD. A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells. Proc Natl Acad Sci USA 1996; 93:11143-11148.
19. Herold BC, Gerber SI, Belval BJ, Siston AM, Shulman N. Differences in the susceptibility of herpes simplex viruses types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J Virol 1996; 70:3461-3469.
20. Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J, De Clerq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp 120 glycoprotein. Mol Pharmacol 1997; 52:98-104.
21. Pope LE, Marcelletti JF, Katz LR, Katz DH. Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug. J Lipid Res 1996; 37:2167-2178.
22. Zeitlin L, Whaley KJ, Sanna PP, et al. Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab′)2 fragments protect mice from vaginal transmission of HSV-2. Virology 1996; 225:213-215.
23. Lampe ME, Ballweber LM, Stamm WE. The antimicrobial peptide D2A21 inhibits the growth of Chlamydia trachomatis in cell culture. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997; abstract O233.
24. Pauwels, R, De Clerq E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acq Immun Def Syndr Hum Retrovirol 1996; 3:211-221.
25. Tevi-Benissan C, Belec L, Levy M, et al. In vivo semen-associated pH neutralization of cervico-vaginal secretions. Clin Diagn Lab Immunol 1997; 4:367-374.
26. Achilles SL, Whaley KJ, Zeitlin L, Moench TR, Cone RA. Evaluating microbicides for preventing chlamydial infection using a mouse model of vaginal transmission. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997, abstract P801.
27. Hawes SE, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacillus and acquisition of vaginal infections. J Infect Dis 1996; 174:1058-1063.
28. Bernstein DI, Miller RL, Harrison CJ. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in quinea pigs after lesion development. Antivir Res 1993; 20:45-55.
29. Stanberry LR. Pathogenesis of herpes simplex virus infection and animal models for its study. Curr Top Microbiol Immunol 1992; 179:15-30.
30. Bravo FJ, Stanberry LR, Kier AB, Vogt PE, Kern ER. Evaluation of HPMPC for therapy of primary and recurrent genital herpes in mice and guinea pigs. Antiviral Res 1993; 21:59-72.
31. Patton DL, Sweeney YC, Rabe LK, Hillier, SL. The vaginal microflora of pig-tailed macaques and the effects of chlorhexidine and benzalkonium on this ecosystem. Sex Trans Dis 1996; 23:489-493.
32. Rank RG, Sanders MM, Patton DL. Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. Sex Transm Dis 1995;22:48-54.
33. Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun 1997; 65:2145-2152.
34. Whaley KJ, Zeitlin L, Barratt RA, Hoen TE, Cone RA. Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. J Infect Dis 1994; 169:647-649.
35. Bishop SA, Strokes CR, Gruffydd-Jones TJ, Whiting CV, Harbour DA. Vaginal and rectal infection of cats with feline immunodeficiency virus. Vet Microbiol 1996; 51:217-227.
36. Burkhartd MJ, Obert LA, O'Neil LL, Diehl LJ, Hoover EA. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13:347-355.
37. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 10:1084-1089.
38. Ziegler JL. A practical method to reduce HIV risk in African women. Trop Doctor 1994; 24:189.
39. Brooks-Gunn J, Paikoff RL. Sex is a gamble, kissing is a game: Adolescent sexuality and health promotion. In: Millstein SG, Peterson AC, Nightingale EO, eds. Promoting the Health of Adolescents: New Directions for the Twenty-first Century. New York, NY: Oxford University Press, 1993:180-208.
40. st Century. New York, NY: Oxford University Press (in press).
41. Crockett LJ, Petersen AC. Adolescent development: Health risks and opportunities for health promotion. In: Millstein SG, Petersen AC, Nightingale EO, eds. Promoting the Health of Adolescents: New Directions for the Twenty-First Century. New York, NY: Oxford University Press, 1993:13-37.
42. Biro FM. Physical growth and maturation. In: Friedman SB, Fisher M, Schonberg SK, eds. Comprehensive Adolescent Health Care. St Louis: Mosby-Year Book (in press).
43. Aral SO, Soskoline V, Joesoef RM, O'Reilly KR. Sex partner recruitment as risk factor for STD: Clustering of risky modes. Sex Transm Dis 1991; 18:10-17.
44. Brooks-Gunn J. Antecedents to and consequences of variations in girls' maturational timing. J Adolesc Health Care 1988; 9:365-373.
45. Sonenstein FL, Pleck JH, Ku LC. Sexual activity, condom use and AIDS awareness among adolescent males. Fam Plann Perspect 1989; 21:152-153.
46. Keating DP, Clark LV. Development of physical and social reasoning during adolescence. Develop Psychol 1980; 16:23-30.
47. Inhelder B, Piaget J. The Growth of Logical Thinking From Childhood to Adolescence. New York, NY: Basic, 1958.
48. Greene AL. Future time-perspective in adolescence: The present of things future revisited. J Youth Adolesc 1986; 15:99-113.
49. Steiner MJ, Glover LH, Bou-saada I, Piedrahita C. Increasing barrier method use among oral contraceptive users at risk of STDs: What approach is best. Sex Trans Dis 1998; 25:139-143.
50. Petersen AC, Leffert N. Developmental issues influencing guidelines for adolescent health research: A review. J Adolesc Health 1995; 17:298-305.
51. Hamburg B. Subsets of adolescent mothers: Developmental, biomedical and psychosocial issues. In: Lancaster JB, Hamburg BA, eds. School-Age Pregnancy and Parenthood: Biosocial Dimensions. New York, NY: Aldine de Gruyter, 1986:115-145.
52. Finkelstein JW, von Eye A. Sanitary product use by white, black, and Mexican American women. Pub Health Rep 1990; 105:491-496.
53. Rogel MJ, Zuehlke ME, Petersen AC, Tobin-Richards M, Shelton M. Contraceptive behavior in adolescence: A decision-making perspective. J Youth Adolesc 1980; 9:491-506.
54. Biglan A, Metzler CW, Wirt R, et al. Social and behavioral factors associated with high-risk sexual behavior among adolescents. J Behav Med 1990; 13:245-261.
55. MacDonald NE, Fisher WA, Wells GA, Doherty JA, Bowie WR. Canadian street youth: Correlates of sexual risk-taking activity. Pediatr Infect J 1994; 13:690-697.
56. Traeen B, Kvalem IL. Sexual socialization and motives for intercourse among Norweigian adolescents. Arch Sex Behav 1996; 25:289-302.
57. Graham A, Green L, Glasier AF. Teenagers' knowledge of emergency contraception: questionnaire survey in south east Scotland. Br Med J 1996;312:1567-1569.
58. Pearson VAH, Owen MR, Phillips DR, Pereira Gray DJ, Marshall MN. Pregnant teenagers' knowledge and use of emergency contraception. Br Med J 1995; 310:1644.
59. Lewis C. How adolescents approach decisions: Changes over grades seven to twelve and policy implications. Child Develop 1981; 52:538-544.
60. Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687-694.
61. Rosenthal SL, Biro FM, Cohen SS, Succop PA, Stanberry LR. Parents, peers, and the acquisition of an STD: Developmental changes in girls. J Adolesc Health 1995; 16:45-49.
62. Rosenthal SL, Kottenhahn RK, Biro FM, Succop PA. Hepatitis B vaccine acceptance among adolescents and their parents. J Adolesc Health 1995; 17:248-254.
63. Rosenthal SL, Cohen SS, Biro FM, DeVellis RF. How do family characteristics relate to interpersonal expectations regarding STD acquisition among adolescent girls? Fam Sys Health 1996; 14: 465-474.
64. Elkind D. Understanding the young adolescent. Adolescence 1978; 8(49):127-134.
65. Quadrel MJ, Fischhoff B, Davis W. Adolescent (in)vulnerability. Am Psychol 1993; 48:102-116.
66. Brown JD, Childers KW, Waszak CS. Television and adolescent sexuality. J Adolesc Health Care 1990; 11:62-70.
67. Lewis, LM, Rosenthal, SL, Melton, RS, Succop, PA. Factors influencing condom use and STD acquisition in African-American college women. Manuscript submitted for publication.
68. Seiving R, Resnick, MD, Bearinger L, Remafedi G, Taylor, BA, Harmon, B. Cognitive and behavioral predictors of sexually transmitted disease risk behavior among sexually active adolescents. Arch Pediatr Adolesc Med 1997; 151:243-251.
69. Norris AE, Ford K, Shyr Y, Schork MA. Heterosexual experiences and partnerships of urban, low-income African-American and Hispanic youth. J of Acq Def Synd and Hum Retrovir 1996; 11:288-300.
70. Jadack RA, Fresia A, Rompalo AM. Zenilman J. Reasons for not using condoms of clients at urban sexually transmitted diseases clinics. Sex Trans Dis 1997; 24:402-408.
71. Kegeles SM, Adler NF, Irwin CF. Sexually active adolescents and condoms: Changes over one year in knowledge, attitudes, and use. Am J Pub Health 1988; 78:460-461.
72. DiClemente RJ. Psychosocial determinants of condom use among adolescents. In: DiClemente RJ, ed. Adolescents and AIDS: A Generation in Jeopardy. Newbury Park, CA: SAGE Publications, 1992:34-51.
73. Donald M, Lucke J, Dunne M, O'Toole B, Raphael B. Determinants of condom use by Australian secondary school students. J Adolesc Health 1994; 15:503-510.
74. St Lawrence JS, Scott CP. Examination of the relationship between African American adolescents' condom use at sexual onset and later sexual behavior: Implications for condom distribution programs. AIDS Prevent Educ 1996; 8:258-266.
75. Hynie M, Lydon, JE. Women's perceptions of female contraceptive • behavior: Experimental evidence of the sexual double standard. Psychol Women Quarterly 1995; 19:563-581.
76. Fullilove MT, Fullilove RE, Haynes K, Gross S. Black women and AIDS prevention: A view towards understanding the gender rules. J Sex Res 1990; 27:47-64.
77. Rosenthal SL, Cohen SS. Primary prevention of sexually transmitted disease: Self-efficacy in the context of sexual coercion. Adolesc Pediatr Gynecol 1994; 7:63-68.
78. Rosenthal SL, Biro FM, Succop PA, Baker JG, Stanberry LR. Reasons for condom utilization among high-risk adolescent girls. Clin Pediatr 1994; 33:706-711.
79. Millstein SG, Moscicki AB. Sexually-transmitted disease in female adolescents: Effects of psychological factors and high risk behaviors. J Adolesc Health 1995; 17:83-90.
80. Visher, S. The relationship of locus of control and contraception use in the adolescent population. J Adolesc Health Care 1986; 7:183-186.
81. St. Lawrence JS. African-American adolescents' knowledge, health-related attitudes, sexual behavior, and contraceptive decisions: Implications for the prevention of adolescent HIV infection. J Consult Clin Psychol 1993; 61:104-112.
82. Gollub EL, Stein Z, El-Sadr W. Short-term acceptability of the female condom among staff and patients at a New York City hospital. Fam Plann Perspect 1995; 27:155-158.
83. Eldridge GD, St. Lawrence JS, Little CE, Shelby MC, Brasfield, TL. Barriers to condom use and barrier method preferences among low-income African-American women. Women Health 1995; 23(1):73-89.
84. Baker JG, Rosenthal SL, Leonhardt D, et al. The relationship between parental monitoring & young adolescent girls' sexual & substance use behaviors. Submitted.
85. Rosenthal SL, Lewis LM, Succop PA, Burklow KA, Biro FM. Adolescent girls' perceived prevalence of sexually transmitted diseases and condom use. J Dev Behav Pediatr 1997; 18:22.
86. Wyatt GE. Examining ethnicity versus race in AIDS-related research Soc Sci Med 1991; 33:37-45.
87. Yee, AH, Fairchild HH, Weizman F, Wyatt, GE. Addressing psychology's problem with race. Am Psychol 1993; 48:1132-1140.
88. Lyons JM, Ito JI. Reducing the risk of Chlamydia tracomatis genital tract infection by evaluating the prophylactic potential of vaginally applied chemicals. Clin Infect Dis 1995; 21(suppl 2):S174-S177.
89. Wainberg MA, Spira B, Bleau G, Thomas R. Inactivation of human immunodeficiency virus type 1 in tissue culture fluid and in genital secretions by the spermicide benzalkonium chloride. J Clin Microbiol 1990; 28:156-158.
90. Pilipenko V, Reising SF, Cooper MD. Potential microbicides for the prevention of Chlamydia trachomatis infection. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997 [abstr P802].
91. Corner A-M, Dolan MM, Yankell SL, Malamud D. C31G, a new agent for oral use with potent antimicrobial and antiadherence properties. Antimicrob Agents Chemother 1988; 32:350-353.
92. Wyrick P, Knight ST, Gerbig DG Jr., et al. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrob Ag Chemother 1997; 41:1335-1344.
93. Zacharopoulos VR, Phillips DM. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin Diagn Lab Immunol 1997; 4:465-468.
94. Bernstein D, Schiff G, Echler, G, Prince A, Feller M, Briner W. In Vitro Virucidal Effectiveness of a 0.12%-Chorhexidine Gluconate Mouthrinse. J Dent Res 1990; 69:874-876.
95. Baba M, Schols D, Nakashima H, et al. Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro. J Acquir Immun Def Synd 1989; 2:264-271.
96. Reising SF, El-Awar FY, Bourne N, Bourne KZ, Stanberry LR. Intravaginal microbicides: Cholic acid activity against herpes simplex virus type-2. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997 [abstract P761].
97. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Ag Chemother 1997;41:1521-1530.
98. Rosenstein LI, Stafford M, Kitchen V, Ward H, Weber JN, Taylor-Robinson D. Effect of intravaginal microbicidal agents on the normal vaginal flora. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997 [abstr P701].
99. Baker GE, Tyring SK. Therapeutic approaches to papillomavirus infections. Derm Clin 1997; 15:331-340.
100. Cohen JS, Cohen A, Thornburgh DB, Mones, JM. Colposcopic evaluation with microbiologic and gynecologic correlation of the GEDA PLUS vaginal microbicide in 279 women. Unpublished report, 1996.
101. Zeitlin L, Cone RA, Moench TR, et al. A human monoclonal antibody produced in plants for preventing genital herpes. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997 [abstr O192].
102. Louv WC, Austin H, Alexander WJ, Stagno S, Cheeks J. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis 1988; 158:518-523.
103. Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991; 18:176-179.
104. Roddy RE, Zekeng L, Ryan KA, Weir SS, Tamouofe U, Wong E. A randomized controlled trial of N-9 film use on male-to-female transmission of HIV-1. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997 [abstr S51].
105. Van Damme L, Depractere K, Van Dyck E, et al. Phase 1 trial of PRO 2000 gel, a new topical microbicide for STD prevention. Abstracts of the 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville, Spain, October, 1997 [abstr O253].
106. Psychoyos A, Creatsas G, Hassan E, Georgoulias V, Gravanis A. Spermcidal and antiviral properties of cholic acid: Contraceptive efficacy of a new vaginal sponge (Protectaid) containing sodium chloate. Hum Reproduct 1993; 6:866-869.
107. Yasin B, Lehrer RI, Harwig SS, Wagar EA. Protegrins: Structural requirements for inactivating elementary bodies of Chlamydia trachomatis. Infect Immun 1996; 11:4863-4866.
108. Qu XD, Harwig SS, Shafer WM, Lehrer RI. Protegrin structure and activity against Neisseria gonorrhoeae. Infect Immun 1997; 65:636-639.